610 related articles for article (PubMed ID: 12698085)
1. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment.
Guthery SL; Heubi JE; Bucuvalas JC; Gross TG; Ryckman FC; Alonso MH; Balistreri WF; Hornung RW
Transplantation; 2003 Apr; 75(7):987-93. PubMed ID: 12698085
[TBL] [Abstract][Full Text] [Related]
2. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
[TBL] [Abstract][Full Text] [Related]
3. Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients.
Manlhiot C; Pollock-Barziv SM; Holmes C; Weitzman S; Allen U; Clarizia NA; Ngan BY; McCrindle BW; Dipchand AI
J Heart Lung Transplant; 2010 Jun; 29(6):648-57. PubMed ID: 20304682
[TBL] [Abstract][Full Text] [Related]
4. Timing of Epstein-Barr virus acquisition and the course of posttransplantation lymphoproliferative disorder in children.
Wu JF; Ho MC; Ni YH; Chen HL; Lu CY; Hsu HY; Lee PH; Chang MH
Transplantation; 2009 Mar; 87(5):758-62. PubMed ID: 19295323
[TBL] [Abstract][Full Text] [Related]
5. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
Hurwitz M; Desai DM; Cox KL; Berquist WE; Esquivel CO; Millan MT
Pediatr Transplant; 2004 Jun; 8(3):267-72. PubMed ID: 15176965
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr virus seronegativity is a risk factor for late-onset posttransplant lymphoroliferative disorder in adult renal allograft recipients.
Shahinian VB; Muirhead N; Jevnikar AM; Leckie SH; Khakhar AK; Luke PP; Rizkalla KS; Hollomby DJ; House AA
Transplantation; 2003 Mar; 75(6):851-6. PubMed ID: 12660514
[TBL] [Abstract][Full Text] [Related]
7. Incidence and outcome of primary Epstein-Barr virus infection and lymphoproliferative disease in pediatric heart transplant recipients.
Zangwill SD; Hsu DT; Kichuk MR; Garvin JH; Stolar CJ; Haddad J; Stylianos S; Michler RE; Chadburn A; Knowles DM; Addonizio LJ
J Heart Lung Transplant; 1998 Dec; 17(12):1161-6. PubMed ID: 9883755
[TBL] [Abstract][Full Text] [Related]
8. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients.
Younes BS; McDiarmid SV; Martin MG; Vargas JH; Goss JA; Busuttil RW; Ament ME
Transplantation; 2000 Jul; 70(1):94-9. PubMed ID: 10919581
[TBL] [Abstract][Full Text] [Related]
9. Posttransplantation lymphoproliferative disorder--the great mimic in liver transplantation: appraisal of the clinicopathologic spectrum and the role of Epstein-Barr virus.
Koch DG; Christiansen L; Lazarchick J; Stuart R; Willner IR; Reuben A
Liver Transpl; 2007 Jun; 13(6):904-12. PubMed ID: 17539010
[TBL] [Abstract][Full Text] [Related]
10. Posttransplant lymphoproliferative disorder.
Everly MJ; Bloom RD; Tsai DE; Trofe J
Ann Pharmacother; 2007 Nov; 41(11):1850-8. PubMed ID: 17940127
[TBL] [Abstract][Full Text] [Related]
11. Slc11a1 (formerly Nramp1) polymorphisms and susceptibility to post-transplant lymphoproliferative disease following pediatric liver transplantation.
Barshes NR; Lee TR; Goss JA; Goodpastor SE; Huls MH; Rooney CM; Karpen SJ; Wyllie S
Transpl Infect Dis; 2006 Jun; 8(2):108-12. PubMed ID: 16734634
[TBL] [Abstract][Full Text] [Related]
12. [Epstein Barr viral load monitoring in mononuclear lymphocytes and serum of renal transplant recipients using a quantitative PCR protocol].
Merlino C; Giacchino F; Bergallo M; Bonello F; Bollero C; Segoloni GP; Cavallo R
G Ital Nefrol; 2003; 20(2):170-5. PubMed ID: 12746803
[TBL] [Abstract][Full Text] [Related]
13. Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients.
Lee TC; Savoldo B; Barshes NR; Rooney CM; Heslop HE; Gee AP; Caldwell Y; Scott JD; Goss JA
Clin Transplant; 2006; 20(3):389-93. PubMed ID: 16824159
[TBL] [Abstract][Full Text] [Related]
14. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center.
Knight JS; Tsodikov A; Cibrik DM; Ross CW; Kaminski MS; Blayney DW
J Clin Oncol; 2009 Jul; 27(20):3354-62. PubMed ID: 19451438
[TBL] [Abstract][Full Text] [Related]
15. Adenotonsillar hypertrophy and Epstein-Barr virus in pediatric organ transplant recipients.
Shapiro NL; Strocker AM
Laryngoscope; 2001 Jun; 111(6):997-1001. PubMed ID: 11404611
[TBL] [Abstract][Full Text] [Related]
16. Utility of head and neck biopsies in the evaluation of posttransplant lymphoproliferative disorder.
Campisi P; Allen UD; Ngan BY; Hawkes M; Forte V
Otolaryngol Head Neck Surg; 2007 Aug; 137(2):296-300. PubMed ID: 17666259
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients.
Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Yegitbasi M; Reinke P; Kebelmann-Betzig C; Hauptmann K; Gross-Wieltsch U; Hetzer R; Berger F
Pediatr Transplant; 2009 Feb; 13(1):54-62. PubMed ID: 18518912
[TBL] [Abstract][Full Text] [Related]
18. Post-transplant lymphoproliferative disorder following pediatric heart transplantation.
Mendoza F; Kunitake H; Laks H; Odim J
Pediatr Transplant; 2006 Feb; 10(1):60-6. PubMed ID: 16499589
[TBL] [Abstract][Full Text] [Related]
19. Impact of immunosuppression on the development of Epstein-Barr virus (EBV) viremia after pediatric liver transplantation.
Lu BR; Park KT; Hurwitz M; Cox KL; Berquist WE
Transplant Proc; 2013; 45(1):301-4. PubMed ID: 23267800
[TBL] [Abstract][Full Text] [Related]
20. Identifying predictive factors for posttransplant lymphoproliferative disease in pediatric solid organ transplant recipients with Epstein-Barr virus viremia.
Weintraub L; Weiner C; Miloh T; Tomaino J; Joashi U; Benchimol C; Strauchen J; Roth M; Wistinghausen B
J Pediatr Hematol Oncol; 2014 Nov; 36(8):e481-6. PubMed ID: 24878618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
